ProCE Banner Activity

SOLACE-kids: Phase II Study of Crizanlizumab in Adolescents With Sickle Cell Disease

Slideset Download
Conference Coverage

Results from an open-label phase II trial showing that crizanlizumab is well tolerated in adolescent patients (aged 12 to <18 years) with SCD and was associated with a reduction in the rate of veno-occlusive crises.

Released: December 15, 2021

Expiration: December 14, 2022

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Daiichi Sankyo, Inc.


Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation